| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B | 4.50B |
| Depreciation and amortization | 1.43B | 1.34B | 1.28B | 1.25B | 1.49B | 1.20B |
| Stock-based compensation | 664.00M | 673.00M | 644.00M | 685.00M | 640.00M | 546.00M |
| Cash from operations | 9.57B | 8.56B | 7.26B | 9.58B | 10.53B | 7.90B |
| Capital expenditure | -2.17B | -2.21B | -2.20B | -1.78B | -1.89B | -2.18B |
| Free cash flow | 7.39B | 6.35B | 5.06B | 7.80B | 8.65B | 5.72B |
| Cash from investing | -2.42B | -2.34B | -3.13B | -1.74B | -2.01B | -2.21B |
| Dividends paid | -4.12B | -3.84B | -3.56B | -3.31B | -3.20B | -2.56B |
| Share buybacks | -893.00M | -1.29B | -1.23B | -3.79B | -2.30B | -403.00M |
| Net debt issued | -44.00M | -52.00M | ||||
| Cash from financing | -6.31B | -5.40B | -7.09B | -7.64B | -5.49B | -2.78B |
| Net change in cash | 906.00M | 720.00M | -2.99B | 83.00M | 2.96B | 2.98B |
From Abbott Laboratories's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.